SG11202108607QA - Crystalline forms of a jak2 inhibitor - Google Patents

Crystalline forms of a jak2 inhibitor

Info

Publication number
SG11202108607QA
SG11202108607QA SG11202108607QA SG11202108607QA SG11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA SG 11202108607Q A SG11202108607Q A SG 11202108607QA
Authority
SG
Singapore
Prior art keywords
hhh
crystalline form
degrees
crystalline
ray powder
Prior art date
Application number
SG11202108607QA
Other languages
English (en)
Inventor
Benoit Robert
Pascal Billot
Original Assignee
Impact Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc filed Critical Impact Biomedicines Inc
Publication of SG11202108607QA publication Critical patent/SG11202108607QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202108607QA 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor SG11202108607QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1902018A FR3092581A1 (fr) 2019-02-12 2019-02-12 Formes cristallines d'un inhibiteur de jak2
PCT/US2020/017764 WO2020167844A1 (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor

Publications (1)

Publication Number Publication Date
SG11202108607QA true SG11202108607QA (en) 2021-09-29

Family

ID=68281482

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108607QA SG11202108607QA (en) 2019-02-12 2020-02-11 Crystalline forms of a jak2 inhibitor

Country Status (13)

Country Link
US (1) US20220332706A1 (cg-RX-API-DMAC7.html)
EP (1) EP3927704A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022520083A (cg-RX-API-DMAC7.html)
KR (1) KR20210148110A (cg-RX-API-DMAC7.html)
CN (1) CN114026088A (cg-RX-API-DMAC7.html)
AU (1) AU2020221796A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015318A2 (cg-RX-API-DMAC7.html)
EA (1) EA202192237A1 (cg-RX-API-DMAC7.html)
FR (1) FR3092581A1 (cg-RX-API-DMAC7.html)
IL (1) IL285427A (cg-RX-API-DMAC7.html)
MX (1) MX2021009423A (cg-RX-API-DMAC7.html)
SG (1) SG11202108607QA (cg-RX-API-DMAC7.html)
WO (1) WO2020167844A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY209349A (en) 2018-09-25 2025-07-03 Impact Biomedicines Inc Methods of treating myeloproliferative disorders
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053452A1 (en) * 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2013013195A1 (en) * 2011-07-21 2013-01-24 Sanofi Compositions and methods for treating polycythemia vera and essential thrombocythemia
JP2020504711A (ja) * 2016-12-21 2020-02-13 バイオセリックス, インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用

Also Published As

Publication number Publication date
MX2021009423A (es) 2021-11-17
EP3927704A1 (en) 2021-12-29
AU2020221796A1 (en) 2021-08-12
JP2022520083A (ja) 2022-03-28
US20220332706A1 (en) 2022-10-20
FR3092581A1 (fr) 2020-08-14
KR20210148110A (ko) 2021-12-07
BR112021015318A2 (pt) 2021-10-05
WO2020167844A1 (en) 2020-08-20
IL285427A (en) 2021-09-30
EA202192237A1 (ru) 2021-12-14
EP3927704A4 (en) 2022-12-28
CN114026088A (zh) 2022-02-08
JP2025032217A (ja) 2025-03-11

Similar Documents

Publication Publication Date Title
US10023577B2 (en) Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof
JP2025032217A (ja) Jak2阻害剤の結晶形態
CN113840604B (zh) Jak2抑制剂的结晶形式
US10150770B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
US11053214B2 (en) Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
EP4186908B1 (en) Jak inhibitor compound and use thereof
WO2020244348A1 (zh) 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型
JP2025505655A (ja) 1-((s)-4-((r)-7-(6-アミノ-4-メチル-3-(トリフルオロメチル)ピリジン-2-イル)-6-クロロ-8-フルオロ-2-(((s)-1-メチルピロリジン-2-イル)メトキシ)キナゾリン-4-イル)-3-メチルピペラジン-1-イル)プロパ-2-エン-1-オンの固体形態
WO2019228171A1 (zh) 一种稠环嘧啶类化合物的盐、晶型及其制备方法和应用
TW202033517A (zh) Bcl-2抑制劑的新穎鹽、相關的結晶形式、其製備方法及包含其之醫藥組合物
US20250101017A1 (en) Salt crystal form and free base crystal form of kinase inhibitor
EP4382528A1 (en) Crystal form of ripk1 inhibitor, acid salt thereof, and crystal form of acid salt thereof
JP2021527120A (ja) 塩形態
US20190322646A1 (en) Crystalline forms of ap26113, and preparation method thereof
US20230192710A1 (en) Jak inhibitor compound and use thereof
TW202506661A (zh) 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法
CN120457133A (zh) Jak1/tyk2抑制剂的多晶型物及其用途
EP3845534A1 (en) Salt form and crystal form of novel azatricyclic compound and use thereof
JP2021527119A (ja) 塩形態
WO2016081538A1 (en) Solid state forms of ceritinib and salts thereof
CA2944150A1 (en) Polymorphic forms and co-crystals of a c-met inhibitor